跳至主要内容
临床试验/NCT04531670
NCT04531670已完成不适用

Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program

University of Connecticut1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年7月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
1
主要终点
Feasibility - participants retained

研究概览

简要总结

This is a pilot study of an integrated rapid access HIV prevention program for People who inject drugs (PWID) called iRaPID. The program incorporates same-day access to Pre-exposure Prophylaxis (PrEP) and Opioid Agonist Therapy (OAT).

详细描述

A Hybrid type 1 implementation science design,will be used to pilot test the APN-led iRaPID program while exploring information on its implementation at multiple time points through the study. The hybrid type 1 pilot trial provides an implementation heuristic to assess potential research questions, perhaps more comprehensively, accurately and certainly earlier than could be achieved in a sequential 'intervention-then-preliminary-pilot study' strategy. In this hybrid type 1 pilot trial, the RCT will be utilized to:

  • Examine feasibility and acceptability among PWID and clinical stakeholders for an adapted APN-delivered, rapid HIV prevention program for PWID (iRaPID) that integrates same-day PrEP and OAT.
  • Estimate the preliminary efficacy of PrEP and OAT uptake in a pilot randomized controlled trial of the iRaPID vs. treatment as usual strategy in PWID without HIV.

To assess future scale-up factors, the Consolidated Framework for Implementation Research (CFIR) will be utilized with the nominal group technique (NGT). It is a conceptual framework developed to guide the assessment of multilevel implementation contexts. The CFIR framework was selected because it provides a structured menu of constructs associated with effective implementation. It consists of 5 domains with 39 underlying constructs. As recommended by Damschroder, in this study 8 CFIR constructs based on the relevancy will be measured.

During the NGT, participants will be asked questions related to the multi-level implementation factors that will be based on the sample guide available on http://cfirguide.org but tailored for PWID. After posing each question, participants silently generate individual ideas. Then, using a round-robin elicitation process, each person contributes ideas that are recorded visually. They then engage in group discussion to clarify and evaluate the ideas. Items are then grouped by consensus with duplicate items removed. Then, each participant casts three votes on items as they deem them important. Votes are immediately tallied, ranked based on total number of votes, and the facilitator leads a final discussion to review the results. Sessions will take 60 minutes and be audio-recorded and transcribed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age ≥18 years
  • •HIV-negative
  • •Reporting injection drug use (past 3 months)
  • •Substantial ongoing risk for HIV acquisition
  • •OUD based on the DSM-V criteria
  • •Stakeholders
  • •Age ≥18 years
  • •APNs, patient navigators, counselors, and administrators who reflect the range of characteristics of staff members that are involved in HIV care to PWID

排除标准

  • •PWID and stakeholders
  • •An individual who meets any of the following criteria will be excluded from participation in this study:
  • •Unable to provide informed consent
  • •Unable to read and understand English

研究组 & 干预措施

iRaPID

Experimental

Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30

干预措施: iRaPID (Behavioral)

Standard of Care

Active Comparator

PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.

干预措施: Standard of Care (Other)

结局指标

主要结局

Feasibility - participants retained

时间窗: 6 months

The number of participants retained will be used as a measurement of feasibility

Feasibility - participants screened

时间窗: 6 months

The number of participants screened will be used as a measure of feasibility

Feasibility - participants randomized

时间窗: 6 months

The number of participants randomized will be used as a measurement of feasibility

Feasibility - participants recruited

时间窗: 6 months

The number of participants recruited will be used as a measurement of feasibility

Feasibility - treatment adherence

时间窗: 6 months

The number of participants that adhere to treatment will be used as a measurement of feasibility

Acceptability

时间窗: 6 months

Acceptability will be measured using a 10-item acceptability rating profile. Acceptability will be based on descriptive statistics from the acceptability measures (score ≥70) and analysis of qualitative data, which will be done using thematic analysis

Uptake of PrEP and OAT

时间窗: 6 month

PrEP uptake proportion at 6-month follow-up will be estimated and compared using linear contrast statement in SAS.

Adherence to PrEP

时间窗: 6 months

Adherence to PrEP will be measured using the visual analogue scale and dried blood spots

Persistence on PrEP

时间窗: 6 months

Persistence on PrEP will be measured by collecting information on refilled within 30 days after exhausting PrEP from previous fill data

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Roman Shrestha

Assistant Professor

University of Connecticut

研究点 (1)

Loading locations...

相似试验

Testing of the Integrated Rapid Access to HIV... | 临床试验